D-Proline

We are D-Proline CAS:344-25-2 manufacturer and supplier in China, Pls send inquiry of to info@nbinno.com of visit www.nbinno.com our official website should you have any interests


D-Proline
CAS RN: 344-25-2
 

Solubility in water	Colorless & clear (c=5)
Specific rotation (20℃)	+ 83.5°～ +86.0°(c= 4,water)
Loss on drying	Not more than 0.4%
Residue on ignition	Not more than 0.1%
Chloride (Cl)	Not more than 0.03%
Sulfate (SO4)	Not more than 0.03%
Heavy metals (as Pb)	Not more than 10ppm
Iron (Fe)	Not more than 10ppm
Ammonium (NH4)	Not more than 0.02%
Arsenic (As2O3)	Not more than 1ppm
Other amino acids	Not detected by T.L.C.(The spotted amount, 20μg)
Assay	98.5%～101.0%
L-Isomer	Not more than 0.5%

 




Related News: The primary endpoint of INSPIRE is overall survival. The trial continued beyond the pre-specified interim analysis and is nearing its conclusion.N1- (2- (dimetilamino) etil) -5-metoxi-N1-metil-N4- (4- (1-metil-1H-indol-3-il) pirimidin-2-il) -2-nitrobenceno-1, 4-diamina CAS:1421372-67-9 According to statistics, in the ten years from 2008 to 2017, a total of 13 “China Class 1” small-molecule chemical drugs were independently researched and developed by domestic enterprises in China and approved by the CFDA; in 2018, there were 10 varieties of domestic Class 1 new drugs. Approved for listing in China.Triacetoxyethylsilane CAS:17689-77-9 From basic chemical raw materials to chemical preparations, complex chemical and physical processes are required. The production of chemical raw materials and intermediates concentrates the main synthetic procedures and technical links, which is the prerequisite and important guarantee for the development of the chemical pharmaceutical industry.Hidrocloruro de ácido 2- (terc-butilamino) acético CAS:6939-23-7 “We believe the iLet Bionics Pancreas System represents a true breakthrough therapy for the management of glycemia, particularly in type 1 diabetes,” said Ed Damiano, President and CEO of Beta Bionics. “We are partuclarly excited by the possibility that the iLet may be able to provide safer and more effective therapy in far more people than current therapies due to its simplicity of use.”Retrogenix and Resonant Therapeutics, Inc. recently announced they have entered into a non-exclusive strategic partnership to identify the targets of Resonant antibodies directed against the tumor microenvironment.